Sun A M
Methods Enzymol. 1988;137:575-80. doi: 10.1016/0076-6879(88)37053-9.
It was about two decades ago that Chang proposed the use of microencapsulated islets as artificial beta cells. By using alginate-poly(L-lysine)-alginate membranes, biocompatible, durable capsules containing viable islet cells can be produced which are impermeable to cells and effector molecules of the immune system, thus providing a total protection to transplanted islets against rejection. The capsule wall contains 93% (w/w) water and can be classified as a hydrogel. Many hydrogels have gained general acceptance as being biocompatible materials. Microencapsulation of pancreatic islets for use as an artificial endocrine pancreas would not only obviate the need for immunosuppressive therapy but also has the potential to prevent the long-term complications of diabetes. Furthermore, the microencapsulation technique can be applied to other types of cells to produce antibodies or enzymes, and to treat a whole range of diseases requiring endocrine replacement therapy.
大约二十年前,张提出使用微囊化胰岛作为人工β细胞。通过使用海藻酸盐-聚(L-赖氨酸)-海藻酸盐膜,可以生产出含有活胰岛细胞的生物相容性、耐用的胶囊,这些胶囊对免疫系统的细胞和效应分子是不可渗透的,从而为移植的胰岛提供全面的抗排斥保护。胶囊壁含有93%(w/w)的水,可归类为水凝胶。许多水凝胶已被广泛认可为生物相容性材料。将胰岛微囊化用作人工内分泌胰腺不仅可以避免免疫抑制治疗的需要,而且有可能预防糖尿病的长期并发症。此外,微囊化技术可应用于其他类型的细胞以产生抗体或酶,并用于治疗一系列需要内分泌替代治疗的疾病。